NCT05118490View on ClinicalTrials.gov

Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

July 19, 2023

Primary Completion Date

October 28, 2024

Study Completion Date

December 31, 2024

Conditions
HIV SeropositivityTuberculosisHousehold Contact
Interventions
DRUG

Daily rifapentine and isoniazid for 4 weeks

Arm A: isoniazid (300mg) and rifapentine (600mg) daily for 4 weeks (1HP)

DRUG

Weekly rifapentine and isoniazid for 12 weeks

Arm B: isoniazid (900mg) and rifapentine (900mg) weekly for 12 weeks (3HP)

Trial Locations (4)

2571

RECRUITING

The Aurum Institute: Gavin J Churchyard Legacy Centre, Klerksdorp

14350

RECRUITING

Yayasan KNCV - The Persahabatan Hospital, Jakarta, Jakarta

411001

RECRUITING

The Byramjee Jeejeebhoy Medical Centre (BJGMC-JHU) CRS, Pune

Unknown

RECRUITING

Fundação Aurum (The Aurum Institute Mozambique), Chokwé

All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

lead

The Aurum Institute NPC

OTHER